Health Assessment, Patient Treatment Satisfaction and Quality-of-Life in Insulin-Naive Type 2 Diabetes Patients

Inclusion criteria: * Patients with type 2 diabetes mellitus (no history of ketoacidosis) according to ADA criteria. * Treatment with a combination of maximum 2 substance classes on a stable dosage during the last 3 months: metformin and/or sulfonylurea. * No pre-treatment with any insulin in the last 3 months before the study. * Glycated Haemoglobin A1c (HbA1c) value between \> or = 7.0 and \> or = 9.5% * Fasting Blood Glucose (FBG) \> or = 120 mg/dl (6.7 mmol/l). * Body mass index \< 40 kg/m. * Ability to read and understand German language. * Ability and willingness to follow a tight antidiabetic therapy and to perform blood glucose self monitoring on a regular basis. * Women of childbearing potential who will take adequate contraceptive protection. Exclusion criteria: * Patients with type 1 diabetes mellitus. * Any history of ketoacidosis. * Pregnancy. * Prior treatment with insulin. * Treatment with more than two oral agents within the last 3 months or continuous treatment with thiazolidinediones, GLP-1 receptor agonists or with Dipeptidyl-Peptidase IV (DPP-IV) inhibitors. * History of drug or alcohol abuse. * Diabetic retinopathy with surgical treatment (laser photocoagulation or vitrectomy) in the last 3 months prior to study entry or which may require surgical treatment within 3 months of study entry. * Following pancreatectomy. * Impaired hepatic function. * Impaired renal function. * Mental condition rendering the patient unable to understand the nature, scope and possible consequences of the study. * Evidence of an uncooperative attitude, including poor compliance to any (antidiabetic) treatment. * Inability to attend follow-up visits. * Current treatment because of a mental disorder according to ICD 10(F 5 Diagnoses). * Patients that are in a relationship of dependance with the investigator(s) and/or the sponsor. * Systemic corticoids \> 7,5 mg prednisolon equivalent or \<or=7,5 mg prednisolon equivalent for less than 2 months. The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.